37872562|t|Bifidobacterium bifidum and Lactobacillus paracasei alleviate sarcopenia and cognitive impairment in aged mice by regulating gut microbiota-mediated AKT, NF-kappaB, and FOXO3a signaling pathways.
37872562|a|Sarcopenia is closely associated with gut dysbiosis. Probiotics alleviate gut dysbiosis. Therefore, we selected probiotics Lactobacillus paracasei P62 (Lp) and Bifidobacterium bifidum P61 (Bb), which suppressed muscle RING-finger protein-1 (MuRF1) expression and NF-kappaB activation in C2C12 cells, and examined their effects on muscle mass loss and dysfunction in aged mice. Oral administration of Lp, Bb, or their mix (LB) increased grip strength and treadmill running distance and time. They significantly increased muscle weight in aged mice. They also increased AKT activation, PGC1alpha, SIRT1, and myosin heavy chain (MyHC) expression, MyHC-positive cell population, and cell size in the gastrocnemius (GA) muscle, while FOXO3a and NF-kappaB activation, MuRF1, muscle atrophy F-box, and p16 expression, and NF-kappaB+CD11c+ cell population decreased. Furthermore, they reduced cognitive impairment-like behavior, IL-6 expression, FOXO3a activation, and NF-kappaB-positive cell population in the hippocampus, GA, and colon, while hippocampal brain-derived neurotropic factor expression increased. They shifted gut microbiota composition in aged mice: they increased Akkermansiaceae and Bacteroidaceae populations, which were positively correlated with total muscle weight and MyHC expression, and decreased Odoribacteraceae and Deferribacteriaceae populations, which were positively correlated with MuRF1 and IL-6 expression. LB alleviated sarcopenia- and cognitive impairment-like symptoms more potently than Lp or Bb alone. Based on these findings, probiotics, particularly Lp, Bb, and LB, can alleviate aging-dependent sarcopenia and cognitive impairment by regulating gut microbiota-mediated AKT, NF-kappaB, and/or FOXO3a signaling pathways.
37872562	62	72	sarcopenia	Disease	MESH:D055948
37872562	77	97	cognitive impairment	Disease	MESH:D003072
37872562	149	152	AKT	Gene	11651
37872562	154	163	NF-kappaB	Gene	18033
37872562	169	175	FOXO3a	Gene	56484
37872562	196	206	Sarcopenia	Disease	MESH:D055948
37872562	234	247	gut dysbiosis	Disease	MESH:D064806
37872562	270	283	gut dysbiosis	Disease	MESH:D064806
37872562	407	435	muscle RING-finger protein-1	Gene	433766
37872562	437	442	MuRF1	Gene	433766
37872562	459	468	NF-kappaB	Gene	18033
37872562	483	488	C2C12	CellLine	CVCL:0188
37872562	526	558	muscle mass loss and dysfunction	Disease	MESH:D009135
37872562	764	767	AKT	Gene	11651
37872562	780	789	PGC1alpha	Gene	19017
37872562	791	796	SIRT1	Gene	93759
37872562	802	820	myosin heavy chain	Gene	111671
37872562	822	826	MyHC	Gene	111671
37872562	840	844	MyHC	Gene	111671
37872562	925	931	FOXO3a	Gene	56484
37872562	936	945	NF-kappaB	Gene	18033
37872562	958	963	MuRF1	Gene	433766
37872562	965	979	muscle atrophy	Disease	MESH:D009133
37872562	991	994	p16	Gene	12578
37872562	1011	1020	NF-kappaB	Gene	18033
37872562	1021	1026	CD11c	Gene	16411
37872562	1081	1101	cognitive impairment	Disease	MESH:D003072
37872562	1117	1121	IL-6	Gene	16193
37872562	1134	1140	FOXO3a	Gene	56484
37872562	1157	1166	NF-kappaB	Gene	18033
37872562	1479	1483	MyHC	Gene	111671
37872562	1602	1607	MuRF1	Gene	433766
37872562	1612	1616	IL-6	Gene	16193
37872562	1643	1653	sarcopenia	Disease	MESH:D055948
37872562	1659	1679	cognitive impairment	Disease	MESH:D003072
37872562	1825	1835	sarcopenia	Disease	MESH:D055948
37872562	1840	1860	cognitive impairment	Disease	MESH:D003072
37872562	1899	1902	AKT	Gene	11651
37872562	1904	1913	NF-kappaB	Gene	18033
37872562	1922	1928	FOXO3a	Gene	56484
37872562	Association	MESH:D003072	11651
37872562	Association	MESH:D003072	56484
37872562	Association	MESH:D055948	18033
37872562	Association	MESH:D055948	11651
37872562	Association	MESH:D055948	56484
37872562	Association	MESH:D003072	18033

